Abstract

Background and aim: Neoplasia related inflammation now is proved to be a factor determining the outcomes in patients with cancer including glioblastoma, we aimed to determine the prognostic value of NLR on the progression free (PFS) and overall survival (OS) for patients with GBM.

Methods: The baseline complete blood picture prior to the initiation of any corticosteroid and cancer therapy (surgery and RT) was obtained then NLR was determined and correlated with PFS and OS for patients with GBM.

Results: patients with NLR ≤4 had a significantly better PFS (the median PFS=12±1.614 months, CI=8.836-15.164 for those with NLR ≤4 vs. a Median PFS=6±1.239 months, CI=3.572-8.428 for those with NLR>4, P<0.009) and OS (the median OS=15±3.627 months, CI=7.890-22.110 vs. a median OS=7±1.038 months, CI=4.966-9.034, P<0.002 for those with NLR≤4 vs. those with NLR>4 respectively). And this effect of NLR was dependant on other prognostic factors.

Conclusion: NLR had a prognostic effect on PFS and OS, but it wasn't an independent factor for survival.

This work is licensed under a Creative Commons Attribution 4.0 License.